Selected-GenAtlas references SOURCE GeneCards NCBI Gene Swiss-Prot Ensembl
HGNC UniGene Nucleotide OMIM UCSC
Home Page
FLASH GENE
Symbol IFNAR1 contributors: mct - updated : 08-03-2015
HGNC name interferon (alpha, beta and omega) receptor 1
HGNC id 5432
Location 21q22.11      Physical location : 34.697.213 - 34.732.126
Synonym name identified by monoclonal antibody IFNaR3
Synonym symbol(s) IFNAR, IFNBR, IFNRA, IFRC, AVP, IFN-alpha-REC
DNA
TYPE functioning gene
STRUCTURE 34.92 kb     11 Exon(s)
10 Kb 5' upstream gene genomic sequence study
MAPPING cloned Y linked Y status confirmed
Map cen - SOD1 - D21S261 - D21S262 - IFNAR2 - IL10RB - IFNAR1 - IFNGR2 - TMEM50B - GART - SON - DONSON - qter
Authors Lutfalla (95),Reboul (99) Wynn (00)
Physical map
C21orf63 21q22.11 chromosome 21 open reading frame 63 C21orf77 21q22.11 chromosome 21 open reading frame 7 TCP10L 21q22.11 t-complex 10 (mouse)-like C21orf59 21q22.1 chromosome 21 open reading frame 59 LOC391279 21 similar to putative taste receptor HTR2 SYNJ1 21q22.1-q22.2 synaptojanin 1 C21orf66 21q22.11 chromosome 21 open reading frame 66 C21orf62 21q22.1 chromosome 21 open reading frame 62 OLIG2 21q22.11 oligodendrocyte lineage transcription factor 2 C21orf54 21q22.11 chromosome 21 open reading frame 54 IFNAR2 21q22.1 interferon (alpha, beta and omega) receptor 2 IL10RB 21q22.1-q22.2 interleukin 10 receptor, beta IFNAR1 21q22.1 interferon (alpha, beta and omega) receptor 1 IFNGR2 21q22.1 interferon gamma receptor 2 (interferon gamma transducer 1) C21orf4 21q22.1-q22.2 chromosome 21 open reading frame 4 RPS5L 21q22.11 ribosomal protein S5-like C21orf55 21q22.11 chromosome 21 open reading frame 55 GART 21q22.1 phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase SON 21q22.1-q22.2 SON DNA binding protein DONSON 21q22.1 downstream neighbor of SON CRYZL1 21q22.1 crystallin, zeta (quinone reductase)-like 1 ITSN1 21q22.1-q22.2 intersectin 1 (SH3 domain protein) ATP5O 21q22.1-q22.2 ATP synthase, H+ transporting, mitochondrial F1 complex, O subunit (oligomycin sensitivity conferring protein) LOC388819 21 similar to GNGT1 protein MRPS6 21q21.3-q22.1 mitochondrial ribosomal protein S6 SLC5A3 21q22.1 solute carrier family 5 (inositol transporters), member 3 C21orf82 21q22.1 chromosome 21 open reading frame 82
RNA
TRANSCRIPTS type messenger
identificationnb exonstypebpproduct
ProteinkDaAAspecific expressionYearPubmed
11 - 6099 - 557 - 1997 9339898
EXPRESSION
Type widely
   expressed in (based on citations)
organ(s)
SystemOrgan level 1Organ level 2Organ level 3Organ level 4LevelPubmedSpeciesStageRna symbol
Digestiveintestinesmall intestine   
Hearing/Equilibriumear   highly
Reproductivefemale systemovary   
Urinarybladder   highly
 kidney   highly
tissue
SystemTissueTissue level 1Tissue level 2LevelPubmedSpeciesStageRna symbol
Blood / hematopoieticbone marrow   
Connectivebone   
cell lineage
cell lines
fluid/secretion
at STAGE
PROTEIN
PHYSICAL PROPERTIES
STRUCTURE
motifs/domains
three fibronectin type III domains
HOMOLOGY
Homologene
FAMILY cytokine receptor family II
CATEGORY signaling cytokine , receptor
SUBCELLULAR LOCALIZATION     plasma membrane
    intracellular
intracellular,cytoplasm,organelle,endosome
intracellular,nucleus
text
  • can translocate to the nucleus following IFN beta stimulation
  • shortly after IFN stimulation, robustly ubiquitinated IFNAR1 were found in the endosomal compartment
  • basic FUNCTION
  • interferon alpha/beta (type I), receptor, alpha subunit conferring high affinity to the receptor
  • functioning as an antiviral factor
  • its ubiquitination promotes its interaction with the AP2 adaptin complex required for the robust internalization of IFNAR1, implicating cooperation between site-specific ubiquitination and the linear endocytic motif in regulating this process
  • trafficking of the IFN receptor (IFNAR1 and IFNAR2) through endosomes may potentially regulate signaling pathways
  • CELLULAR PROCESS
    PHYSIOLOGICAL PROCESS
    PATHWAY
    metabolism
    signaling
    a component
    INTERACTION
    DNA
    RNA
    small molecule
    protein
  • associating with TYK2 and positively influencing ligand binding to the receptor complex (catalytic activation of TYK2 is not essential for IFNAR1 internalization, but is required for ligand-induced IFNAR1 serine phosphorylation, ubiquitination and efficient lysosomal proteolysis)
  • TRAF2 rapidly binds to the IFNAR1 subunit of the IFN receptor upon IFN binding (role of TRAF2 binding to the type I interferon receptor in alternative NF kappaB activation and antiviral response)
  • intercating with IFNA1 (palmitoylation of IFNAR1 is required for the activation of STAT1 and STAT2 by IFNA1)
  • expression and kinase activity of PRKD2 are required for the ligand-inducible stimulation of IFNAR1 ubiquitination and endocytosis and for accelerated proteolytic turnover of IFNAR1
  • PTPN1 is a specific regulator of IFNAR1 endocytosis stimulated by IFN1, but not by ligand-independent inducers of IFNAR1 ubiquitination
  • . PTPN1 is a specific regulator of IFNAR1 endocytosis stimulated by IFN1, but not by ligand-independent inducers of IFNAR1 ubiquitination
  • TYK2-IFNAR1 interface reveals an unexpected receptor-binding mode that mimics a SH2 domain-phosphopeptide interaction, with a glutamate replacing the canonical phosphotyrosine residue
  • ZG16B conferred resistance to pancreatic cancer cells against oncolytic parvovirus H-1 infection through IFNAR1-mediated signaling
  • cell & other
    REGULATION
    Other inducible priming phosphorylation promotes ligand-independent degradation of the IFNAR1 chain of type I interferon receptor
    ASSOCIATED DISORDERS
    corresponding disease(s)
    Susceptibility
  • to chronic HBV infection
  • to multiple sclerosis
  • Variant & Polymorphism SNP , other
  • two linked single nucleotide polymorphisms (SNPs) at -408 and -3 of IFNAR1 promoter are associated with susceptibility to chronic HBV infection
  • IFNAR1 mRNA level is lower in multiple sclerosis patients than in healthy controls
  • Candidate gene
    Marker
    Therapy target
    ANIMAL & CELL MODELS